ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: TH-PO424

Combined Treatment with Cholecalciferol and Omega-3 Fatty Acid Modulates Molecules Associated with Sarcopenia and Cardiac Hypertrophy in 5/6 Nephrectomy Rats

Session Information

Category: Nutrition, Inflammation, and Metabolism

  • 1401 Nutrition, Inflammation, Metabolism

Authors

  • Choi, Hyuck jae, Dong-A university hospital, Pusan, Korea (the Republic of)
  • Lee, Su mi, Seoul National University Hospital, Seoul, SEOUL, Korea (the Republic of)
  • Son, Sung Hyun, BHS Han Seo Hospital, Suyeong-gu,, Busan, Korea (the Republic of)
  • Kim, Kitae, Dong-A university hospital, Pusan, Korea (the Republic of)
  • Son, Young ki, Dong-A University, Busan, Korea (the Republic of)
  • Kim, Seong Eun, Dong-A University Hospital , Busan, Korea (the Republic of)
  • An, Won Suk, Dong-A University, Busan, Korea (the Republic of)
Background

Cardiac hypertrophy and sarcopenia are common in dialysis patients and result in high probability for morbidity and mortality. Akt-mTOR axis is related with cardiac hypertrophy and muscle atrophy. The present study aimed to investigate whether omega-3 fatty acid (O-3FA) and cholecalciferol (Vit. D) affect on molecules associated with cardiac hypertrophy and sarcopenia in 5/6 Nx. rats.

Methods

Male Sprague Dawley rats were divided into 5 groups and treated for 6 weeks: sham control, 5/6 subtotal Nx control, 5/6 Nx treated with Vit.D, 5/6 Nx treated with O-3 FA, 5/6 Nx treated with Vit. D and O-3 FA. The expression of myostatin, myogenin, MyoD, Akt, phosphrylated(p) Akt and mTOR were examined by western blot analysis.

Results

Serum BUN and creatinine were the lowest in 5/6 Nx group treated with O-3 FA and Vit. D among other 5/6 Nx groups. Compared with sham control, 5/6 Nx control significantly up-regulated myostatin and down-regulated myogenin and MyoD in both cardiac and skeletal muscle. Increased expression of myostatin and decreased expression of myogenin and MyoD of cardiac and skeletal muscle were recovered by combined treatment with O-3 FA and Vit. D. Phosphorylated Akt and mTOR were up-regulated in the cardiac muscle but down-regulated in the skeletal muscle of 5/6 Nx control compared to sham control. Combined therapy of O-3 FA and Vit. D decreased p-Akt and mTOR expression in cardiac muscle and increased p-Akt and mTOR expression in skeletal muscle of 5/6 Nx rats.

Conclusion

Combined therapy of O-3 FA and Vit. D may be helpful for decreasing cardiac hypertrophy and sarcopenia by increasing myogenin and MyoD, decreasing myostatin and modulating Akt-mTOR axis in both cardiac and skeletal muscle of 5/6 Nx rats.

Laboratory results
 Normal control5/6 Nx5/6 Nx with Vit. D5/6 Nx with O-3 FA5/6 Nx with O-3 FA and Vit. DP value
BUN(mg/dL)17.7±1.577.7±28.4*75.3±22.1*63.9±17.0*51.3±8.7*ab0.003
Creatinine(mg/dL)0.4±0.01.3±0.6*1.2±0.3*1.0±0.3*0.8±0.1*abc0.002

Data are expressed as mean ± SD *P value < 0.05 (mean values are significantly different from control) aP value < 0.05 (mean values are significantly different from 5/6 nephrectomy group) bP value < 0.05 (mean values are significantly different from 5/6 nephrectomy c Vitamin D group) cP value < 0.05 (mean values are significantly different from 5/6 nephrectomy c omega-3 FA group)

Funding

  • Private Foundation Support